The DOI matches its Crossref record; 134 of the 135 references it cites were found in a registry or an index.
Controlling AAV Tropism in the Nervous System with Natural and Engineered Capsids
Open accessAbstract
More than one hundred naturally occurring variants of adeno-associated virus (AAV) have been identified, and this library has been further expanded by an array of techniques for modification of the viral capsid. AAV capsid variants possess unique antigenic profiles and demonstrate distinct cellular tropisms driven by differences in receptor binding. AAV capsids can be chemically modified to alter tropism, can be produced as hybrid vectors that combine the properties of multiple serotypes, and can carry peptide insertions that introduce novel receptor-binding activity. Furthermore, directed evolution of shuffled genome libraries can identify engineered variants with unique properties, and rational modification of the viral capsid can alter tropism, reduce blockage by neutralizing antibodies, or enhance transduction efficiency. This large number of AAV variants and engineered capsids provides a varied toolkit for gene delivery to the CNS and retina, with specialized vectors available for many applications, but selecting a capsid variant from the array of available vectors can be difficult. This chapter describes the unique properties of a range of AAV variants and engineered capsids, and provides a guide for selecting the appropriate vector for specific applications in the CNS and retina.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“With translational studies in mind, it is important to demonstrate consistent tropism of a particular rAAV, as examples where the tropism of a given rAAV capsid does not remain consistent in rodents and higher animals have been described [7].”
From Novel oligodendroglial alpha synuclein viral vector models of multiple system atrophy: studies in rodents and nonhuman primates (2017) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“we performed co-labeling via IHC and confirmed the results of previous studies (Castle et al., 2016; Hudry et al., 2016; Schuster et al., 2014; Aschauer et al., 2013; Hinderer et al., 2014; Samaranch et al., 2012), showing that AAV9, when injected directly into the adult brain parenchyma, is not expressed in microglia and minimally expressed in astrocytes (Figure S5).”
From The neuronal retromer can regulate both neuronal and microglial phenotypes of Alzheimer's disease (2022) · cites this paper as Castle et al., 2016
Experimental — accuracy not yet measuredIn the citing paper
“RPE cells can be targeted using AAV1, AAV4, or AAV6 vectors or with the engineered AAV2-7m8 vector, and photoreceptors and Müller glial cells are targeted by serotypes AAV2, AAV5, AAV6, AAV7, AAV8, and AAV9 as well as engineered AAV2-7m8 and AAV8BP2 vectors.56,112–116”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [112]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456
Summerford, C., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1438-1445.1998 · Cited by 1,409 · cited 1×
“For many AAV serotypes cellular surface receptors or binding determinants have been identified, including sialic acid for AAVs 1, 4, 5, and 6 [7, 8], heparan sulfate proteoglycan (HSPG) for AAV2 [9], the laminin receptor for AAV8 [10], and galactose for AAV9 [11, 12].”
BackgroundClades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070 · cited 1×
“However, a large number of alternative capsid variants have been identified from humans, baboons, chimpanzees, and rhesus, pigtailed, and cynomolgus macaques [5, 6].”
BackgroundSelf-citationBurger, C., Gorbatyuk, O. S., Velardo, M. J., Peden, C. S., Williams, P., Zolotukhin, S., Reier, P. J., Mandel, R. J., & Muzyczka, N. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.05.024 · Cited by 741 · cited 2×
“AAV2 diffuses less readily through both the brain and spinal cord parenchyma when compared against other serotypes, and therefore mediates transduction over a smaller area [19, 28, 32, 33].”
BackgroundDalkara, D., Byrne, L. C., Klimczak, R. R., Visel, M., Yin, L., Merigan, W. H., Flannery, J. G., & Schaffer, D. V. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005708 · Cited by 734
αVβ5 integrin: a co-receptor for adeno-associated virus type 2 infection
Summerford, C., Bartlett, J. S., & Samulski, R. J. (1999) · Nature Medicine · doi:10.1038/4768 · Cited by 711
Zhong, L., Li, B., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Cooper, M., Herzog, R. W., Zolotukhin, I., Warrington, K. H., Weigel-Van Aken, K. A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802866105 · Cited by 558
Directed evolution of adeno-associated virus yields enhanced gene delivery vectors
Maheshri, N., Koerber, J. T., Kaspar, B. K., & Schaffer, D. V. (2006) · Nature Biotechnology · doi:10.1038/nbt1182 · Cited by 538 · cited 1×
“In addition to peptide insertion, the development of capsid shuffling [93] and directed evolution [94], discussed in Chapter 11, has generated many promising novel AAV variants.”
BackgroundDavidson, B. L., Stein, C. S., Heth, J. A., Martins, I., Kotin, R. M., Derksen, T. A., Zabner, J., Ghodsi, A., & Chiorini, J. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3428 · Cited by 531 · cited 5×
“AAVs 1, 2, 4, 5, 6, and 8 do not appear to extensively penetrate the brain parenchyma when administered to the CSF [ 22 , 39 , 40 ].”
InfluentialGray, S. J., Matagne, V., Bachaboina, L., Yadav, S., Ojeda, S. R., & Samulski, R. J. (2011) · Molecular Therapy · doi:10.1038/mt.2011.72 · Cited by 501
Cited by
Sorted by citations
Items 101–154 of 154
Daci, R., Gray‐Edwards, H. L., Shazeeb, M. S., Vardar, Z., Vachha, B. A., Cataltepe, O. I., & Flotte, T. R. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.057 · Cited by 7
“17 A recent study in the minipig showed that MRI-guided thalamic injection of AAV5 can mediate transduction of the basal ganglia, the midbrain, and the frontal cortex by way of anterograde transport.”
Avian Adeno-Associated Viral Transduction of the Postembryonic Chicken Retina
Waldner, D. M., Visser, F., Fischer, A. J., Bech‐Hansen, N. T., & Stell, W. K. (2019) · Translational Vision Science & Technology · doi:10.1167/tvst.8.4.1 · Cited by 6
“Retinal cell type-specific tropism has also been reported in other AAV serotypes and is likely a result of differences in receptor binding due to variations in viral capsid structure.(45) The cell-surface receptor/binding determinant recognized by A3V has yet to be determined, and its eventual discovery may explain th…”
BackgroundCong, W., Shi, Y., Qi, Y., Wu, J., Gong, L., & He, M. (2020) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2020.108629 · Cited by 7
GFP-on mouse model for interrogation of in vivo gene editing
Dib, C., Queenan, J. A., Swartzrock, L., Willner, H., Denis, M., Ahmed, N., Zada, F. M., Borges, B., Charlesworth, C. T., Lum, T., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-61449-y · Cited by 5
RNA-programmable cell-type monitoring and manipulation in the human cortex with CellREADR
Matthews, E. A., Russ, J. B., Qian, Y., Zhao, S., Thompson, P., Methani, M., Vestal, M. L., Huang, Z. J., & Southwell, D. G. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116037 · Cited by 5
Sehara, Y., Hayashi, Y., Ohba, K., Uchibori, R., Urabe, M., Inutsuka, A., Shimazaki, K., Kawai, K., & Mizukami, H. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.106 · Cited by 6
“33,38 In this study, we chose gerbils to investigate the tropism to neural stem cells.”
Culture of Human Retinal Explants for Ex Vivo Assessment of AAV Gene Delivery
Wu, W.-H., Tso, A., Breazzano, M. P., Jenny, L. A., Levi, S. R., Tsang, S. H., & Quinn, P. M. J. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2651-1_28 · Cited by 5
Gene therapy and respiratory neuroplasticity
Mantilla, C. B. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.09.014 · Cited by 5
“grade and retrograde axonal transport are important characteristics of AAV (Castle et al., 2016).”
BackgroundMixture interactions at mammalian olfactory receptors are dependent on the cellular environment
Corey, E. A., Zolotukhin, S., Ache, B. W., & Ukhanov, K. (2021) · Scientific Reports · doi:10.1038/s41598-021-88601-0 · Cited by 5
Considerations for the Use of Viral Vectors in Nonhuman Primates
Bohlen, M. O., & Tremblay, S. (2023) · Neuromethods · doi:10.1007/978-1-0716-2918-5_16 · Cited by 4
Spinal premotor interneurons controlling antagonistic muscles are spatially intermingledPreprint
Ronzano, R., Skarlatou, S., Barriga, B. K., Bannatyne, B. A., Bhumbra, G. S., Foster, J. D., Moore, J. D., Lancelin, C., Pocratsky, A. M., Özyurt, M. G., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.10.430608 · Cited by 5
Hagen, C. W., Hoxha, M., Chitale, S., White, A. O., Ogállar, P. M., Expósito, A. N., Agüera, A. D. R., Torres, C., Papini, M. R., & Sabariego, M. (2024) · Hippocampus · doi:10.1002/hipo.23642 · Cited by 4
“Moreover, the AAV2 vector serotype was chosen given its low diffusion rate through brain tissue (Castle et al. 2016), which aids in the localization of expression to infusion sites with minimal spread to other areas including the ventral regions of the HC.”
Dou, D., Lu, J., Chen, X., & Zhang, X. (2025) · Pharmaceutical Research · doi:10.1007/s11095-025-03931-2 · Cited by 4
“CNS-directed gene therapy should be targeting the appropriate cell type(s) in target tissue(s) to achieve life-long treatment minimally invasive delivery following a single dose [5].”
InfluentialTavira, A., Basurco, L., Abellanas, M. A., Ayerra, L., Vidaurre, C., Luquin, E., Vales, Á., González‐Aseguinolaza, G., Marrodán, L., Alonso, M. M., et al. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01158-x · Cited by 3
Masseck, O. A. (2018) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-812028-6.00015-x · Cited by 2
Craniotomy Procedure for Visualizing Neuronal Activities in Hippocampus of Behaving Mice
Wang, Y., Zhu, D., Liu, B., & Piatkevich, K. D. (2021) · Journal of Visualized Experiments · doi:10.3791/62266 · Cited by 3
Sehara, Y., Hashimotodani, Y., Watano, R., Ohba, K., Uchibori, R., Shimazaki, K., Kawai, K., & Mizukami, H. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04200-w · Cited by 4
“To date, over one hundred natural variants of AAV have been identified, and natural serotypes of AAV1, 2, 5, 8, 9, and rh10 are the most commonly used for central nervous system applications [52].”
BackgroundVirus-Based Neural Circuit Tracing
Xu, F., & Liu, Q. L. (2024) · Advances in neurobiology · doi:10.1007/978-3-031-69188-1_5 · Cited by 3
Polysorbates and poloxamer rescue filter-induced serotype-dependent loss of AAVs
Patrick, C., Petroff, M., Plegaria, J. S., Razinkov, V. I., Padmakumar, S., & Mallela, K. M. G. (2025) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2025.103825 · Cited by 3
In vivo applications of chemogenetics in redox (patho)biology
Sorrentino, A., Eroğlu, E., & Michel, T. M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-818606-0.00007-9 · Cited by 2
Calvo-López, T., Grueso, E., Sánchez-Martı́nez, C., & Almendral, J. M. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1063706 · Cited by 3
“However, the restriction to retarget MVM with exogenous VEbp is consistent with the encountered difficulties to retarget the parvovirus adeno-associated virus (AAV) with exogenous peptides (Allaume et al., 2012; Castle et al., 2016).”
BackgroundKumar, P. (2019) · Materials and Methods · doi:10.13070/mm.en.9.2713 · Cited by 3
Nakashima, K. T., Wang, S., & Castle, M. J. (2025) · Brain Sciences · doi:10.3390/brainsci15101058 · Cited by 2
“Adeno-associated virus (AAV) vectors are commonly used for recombinant gene delivery to CNS neurons in animal models and humans [12,13].”
Self-citationYe, Q., Gast, G., Holmes, T. C., & Xu, X. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.107139 · Cited by 2
Targeted approaches to delineate neuronal morphology during early development
Liu, B., Li, Y., Ren, M., & Li, X. (2023) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1259360 · Cited by 2
“Adeno-associated viruses (AAV) have the advantages of versatility and multiple serotypes, rendering them a popular tool in the field of neuroanatomy (Castle et al., 2016; Hammond et al., 2017).”
Regulatory Elements for Gene Therapy of Epilepsy
Chesnokova, E., Bal, N. V., Alhalabi, G., & Balaban, P. M. (2025) · Cells · doi:10.3390/cells14030236 · Cited by 2
Viral Vector Gene Delivery to the Brain for Treating Neurogenetic Diseases
Ramos, L., Hunter, J. E., & Wolfe, J. H. N. (2017) · Springer eBooks · doi:10.1007/978-3-319-57696-1_4 · Cited by 2
Self-citationGonzalez‐Ramos, A., Berglind, F., Kudláček, J., Rocha, E. R., Melin, E., Sebastião, A. M., Valente, C. A., Ledri, M., Andersson, M., & Kokaia, M. (2024) · Gene Therapy · doi:10.1038/s41434-024-00493-7 · Cited by 1
“In these cases, the gene of interest is delivered by the injection of viral vectors containing the gene sequence, which will then be expressed in speci fi c cell types depending upon the promoter and the tropism of the viral vector serotype used [34].”
Zappala, A., Li, H., & Inoue, K. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.108 · Cited by 1
Bjornson, K. J., & Cahill, M. E. (2025) · Biological Psychiatry · doi:10.1016/j.biopsych.2025.11.022 · Cited by 1
Viral and non-viral cellular therapies for neurodegeneration
Srivastav, J., & Sharma, S. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2025.1718669 · Cited by 1
Optimized genetic tracers for viral mediated neuronal projection mapping
Dulin, J. N., Li, Y., Grider, T. L., Rizzo, A., Rosenzweig, E. S., Weber, J., Ramakrishnan, C., Hsueh, B., Deisseroth, K. A., Tuszynski, M. H., et al. (2026) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-026-00894-z · Cited by 2
“The COMET system can also be integrated with a broad range of genetic targeting strategies, including cell-type-specific promoters [3–5], recombinase-dependent expression [6–8], intersectional labeling schemes [9, 10], and retrograde viral delivery [34].”
Cona, A., Newbold, E. J., Kesmen, D., Snape, R., Danner, J., White, N., Borden, W., Iseson, A., Schanz, S. J., Chandler-Militello, D., et al. (2026) · Nature Biotechnology · doi:10.1038/s41587-026-03185-2 · Cited by 3
Therapeutic targeting non-coding RNAs
Ray, R. M., Lazăr, A. D., Balahura, L.-R., Dobranici, A., Costache, M., & Dinescu, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-90406-3.00006-3 · Cited by 1
Cona, A., Newbold, E. J., Kesmen, D., Snape, R., Danner, J., White, N., Borden, W., Iseson, A., Schanz, S. J., Chandler-Militello, D., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.03.662612 · Cited by 1
Weber‐Adrian, D. (2017) · TSpace (University of Toronto)
Digital Droplet PCR Method for the Quantification of AAV Transduction Efficiency in Murine Retina
Okan, I. C. T., Ahmadian, M., Tutuncu, Y., Altay, H. Y., & Ağca, C. (2021) · Journal of Visualized Experiments · doi:10.3791/63038
Craniotomy Procedure for Visualizing Neuronal Activities in Hippocampus of Behaving Mice
Wang, Y., Zhu, D., Liu, B., & Piatkevich, K. D. (2021) · Journal of Visualized Experiments · doi:10.3791/62266-v
Brownstone, R. M. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735350403.793560710
Intrathecal Delivery of Viral Vector-Mediated Gene Therapy
Keifer, O. P. (2023) · Springer eBooks · doi:10.1007/978-3-031-39558-1_16
CRISPR/Cas9 gene editing: A new hope for Parkinson's disease
Hanjankar, S. N., Haria, A., Agarwal, R., & Patravale, V. B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23841-3.00023-6 · Cited by 1
Widespread Transduction of Mouse Neocortical Neurons by Subarachnoid Injection of AAV2
Smirnova, M. P., Osipova, A. A., Borodinova, A. A., Bagrinovtseva, T. M., Dobryakova, Y. V., Смирнов, И. В., & Malyshev, A. Y. (2025) · Journal of Visualized Experiments · doi:10.3791/68235
Lu, W.-H., Chang, T.-T., Chang, Y.-M., Liu, Y.-H., Lin, C.-H., Suen, C.-S., Hwang, M.-J., & Huang, Y.-S. (2024) · Figshare · doi:10.6084/m9.figshare.26748293
Lu, W.-H., Chang, T.-T., Chang, Y.-M., Liu, Y.-H., Lin, C.-H., Suen, C.-S., Hwang, M.-J., & Huang, Y.-S. (2024) · Figshare · doi:10.6084/m9.figshare.26264917
Lu, W.-H., Chang, T.-T., Chang, Y.-M., Liu, Y.-H., Lin, C.-H., Suen, C.-S., Hwang, M.-J., & Huang, Y.-S. (2024) · Figshare · doi:10.6084/m9.figshare.26748296
Lu, W.-H., Chang, T.-T., Chang, Y.-M., Liu, Y.-H., Lin, C.-H., Suen, C.-S., Hwang, M.-J., & Huang, Y.-S. (2024) · Figshare · doi:10.6084/m9.figshare.26265138
Lu, W.-H., Chang, T.-T., Chang, Y.-M., Liu, Y.-H., Lin, C.-H., Suen, C.-S., Hwang, M.-J., & Huang, Y.-S. (2024) · Figshare · doi:10.6084/m9.figshare.26748299
Adeno-associated virus-induced neurotoxicity is prevented by CpG depletion
Dunn, C. E., Carvajal, B. V., Ma, J., Castaneda-Hernandez, G., Nguyen, A. V., Jung, C., Suriano, C. M., & Boulanger, L. M. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201703
“6 In most tissues, the host immune response can pose significant challenges to AAV-mediated gene delivery.”
Achieving cell-type specific transduction with adeno-associated viral vectors in pigeons
Tuff, J. M., Haselhuhn, K. B., Surdin, T., Herlitze, S., Ziegler, M., Güntürkün, O., & Rook, N. (2026) · Current Research in Neurobiology · doi:10.1016/j.crneur.2026.100157
“Interestingly, AAV8 has been reported to transduce non-neuronal cells, such as oligodendrocytes and astrocytes, more efficiently than other serotypes (Castle et al., 2016; Aschauer et al., 2013).”
Jony, M. J. H., Moore, E. D., Dash, A. K., & Shukla, S. (2026) · Current Drug Delivery · doi:10.2174/0115672018409641251130113502
Overview of the DREADDs chemogenetics and the patent landscape of their actuators
Dutta, S., & Iyer, M. R. (2026) · Medicinal Chemistry Research · doi:10.1007/s00044-026-03585-8
Roman, A., Sorensen, M., de Velasco, E. M. F., Parr, A. M., Grande, A. W., & Low, W. C. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48080786
“AAV9 in particular has a broad tropism, able to infect a wide range of CNS cells in addition to peripheral tissue [50,51].”
Köhler, F., Heß, K., Koloske, C., Gaunitz, F., Rosahl, S. K., Gerlach, R., & Kallendrusch, S. (2026) · Journal of Neuro-Oncology · doi:10.1007/s11060-026-05807-w
“This observation is consistent with the broad CNS tropism reported for naturally occurring AAV serotypes [40, 41 ] and underscores the importance of considering off-tar - get transduction during the development of GBM-directed gene therapies.”
Metadata
- Authors
- Castle, M. J., Turunen, H. T., Vandenberghe, L. H., & Wolfe, J. H.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Massachusetts Eye and Ear Infirmary (US)
- Corresponding author
- Wolfe, John H.
- Venue
- Methods in Molecular Biology
- Publisher
- Springer New York
- Published
- 2016
- Volume
- 1382
- Pages
- 133-149
- ISSN
- 1064-3745 (ISSN-L)
- 1940-6029
- PMC
- PMC4993104
- OpenAlex
- W2176154815
- Cited by
- 151
- References
- 135
- Citations by year
- 2026: 9 · 2025: 16 · 2024: 22 · 2023: 15 · 2022: 10 · 2021: 24 · 2020: 14 · 2019: 17 · 2018: 8 · 2017: 11 · 2016: 5
- FWCI
- 23.28
- Type
- book chapter
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- Methods in molecular biology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (1dp1od008267-01)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK063973)
- National Institute of Neurological Disorders and Stroke (R01NS038690, T32NS007413)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (U01HD079066)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- adeno-associated virus, AAV capsid engineering, viral tropism, retinal gene delivery, receptor binding, peptide insertion, directed evolution, neutralizing antibodies, transduction efficiency, vector selection
- MeSH terms
- Dependovirus, Animals, Capsid, Central Nervous System, Genetic Vectors, Humans, Organ Specificity, Retina, Gene Transfer Techniques, Viral Tropism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
